Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $38

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $32 to $38.

byBenzinga Newsdesk

February 28, 2023

1 minute read

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $32 to $38.

Credit Suisse Reiterates Outperform on Dover, Maintains $174 Price Target

By Benzinga Newsdesk

Today, 8:23 AM

Credit Suisse analyst Guy Hardwick reiterates Dover (NYSE:DOV) with a Outperform and maintains $174 price target.

DOV

HV Bancorp Q2 EPS $0.31 Down From $0.63 YoY

By Benzinga Newsdesk

Today, 8:23 AM

HV Bancorp (NASDAQ:HVBC) reported quarterly earnings of $0.31 per share. This is a 50.79 percent decrease over earnings of $0.63 per share from the same period last year.

HVBC

Analyst Ratings

What 11 Analyst Ratings Have To Say About Marqeta

By Benzinga Insights

Today, 8:23 AM

Analysts have provided the following ratings for Marqeta (NASDAQ:MQ) within the last quarter:

Analysis: Did Will Smith Leave Apple Stuck With A Toxic ‘Emancipation’?

By Phil Hall

Today, 8:23 AM

Apple Inc. (NASDAQ: AAPL) came away from last week’s Academy Awards ceremony in equal states of euphoria and agita.

AAPL

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $38

Related Posts

Credit Suisse Reiterates Outperform on Dover, Maintains $174 Price Target

HV Bancorp Q2 EPS $0.31 Down From $0.63 YoY

What 11 Analyst Ratings Have To Say About Marqeta

Analysis: Did Will Smith Leave Apple Stuck With A Toxic ‘Emancipation’?